Optic neuritis (ON) represents around 30% of clinical presentation of clinically isolated syndrome (CIS). Asymptomatic optic nerve involvement is very frequent in all stage of multiple sclerosis (MS) disease including the CIS. However, optic nerve is still not part of MS diagnosis criteria. The main objective of our regional and multicenter study is to evaluate the prognostic value of optic nerve involvement at the earliest clinical stage of MS (=CIS) for the diagnosis of clinically definite MS (2nd clinical relapse) and the delay until the 2nd relapse.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
200
Systematic optic nerve MRI sequence during the CIS diagnosis work-up. This sequence is not done systematically and not recommended for now (except in case of acute ON). The interventional nature of the study remains minimal
Hôpital Roger Salengro
Lille, France
RECRUITINGOptic nerve involvement defined by occurrence of a recent clinical episode of ON
Time frame: assessed at baseline
Asymptomatic optic nerve involvement defined by MRI (detection of an optic nerve T2 hypersignal)
Time frame: assessed at baseline
Risk of a new clinical relapse will be assessed by the occurrence and time to onset of a second MS clinical relapse
Time frame: assessed every 6 months during 24 months
Asymptomatic optic nerve involvement defined by OCT (GCIPL-IETD,3pm)
Time frame: assessed at baseline
Risk of a new clinical relapse will be assessed by the occurrence and time to onset of a CDMS
Time frame: assessed every 6 months during 24 months
Asymptomatic optic nerve involvement will be defined by: - asymptomatic optic nerve T2 hypersignal detected on one or both optic nerve(s) - or by GCIPL-IETD,3pm measured by OCT - or by GCIPL-IETD≥3µm measured by OCT
Time to the second clinical relapse occurrence will be assessed every 6 months during 24 months at each neurological examination (M0, M6, M12, M18, M24)
Time frame: assessed at baseline every 6 months during 24 months
Time to the second clinical relapse occurrence will be assessed every 6 months during 24 months at each neurological examination
Time frame: assessed at Month 0, Month 6, Month 12, Month 18, Month 24
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.